|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-9-24
|
|
pubmed:abstractText |
Tacrolimus (TAC) with mycophenolate mofetil (MMF) and a steroid-free regimen seems to have good efficacy in preventing acute rejection in cardiac transplant recipients, although concern exists about nephrotoxicity. Induction therapy with Daclizumab seems to give protection without side effects. Data are lacking about the outcome of 2-dose Daclizumab+TAC+MMF and a steroid-free regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0041-1345
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2163-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17889125-Adrenal Cortex Hormones,
pubmed-meshheading:17889125-Aged,
pubmed-meshheading:17889125-Antibodies, Monoclonal,
pubmed-meshheading:17889125-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17889125-Drug Administration Schedule,
pubmed-meshheading:17889125-Drug Therapy, Combination,
pubmed-meshheading:17889125-Female,
pubmed-meshheading:17889125-Follow-Up Studies,
pubmed-meshheading:17889125-Graft Rejection,
pubmed-meshheading:17889125-Heart Transplantation,
pubmed-meshheading:17889125-Humans,
pubmed-meshheading:17889125-Immunoglobulin G,
pubmed-meshheading:17889125-Immunosuppressive Agents,
pubmed-meshheading:17889125-Male,
pubmed-meshheading:17889125-Middle Aged,
pubmed-meshheading:17889125-Mycophenolic Acid,
pubmed-meshheading:17889125-Retrospective Studies,
pubmed-meshheading:17889125-Survival Analysis,
pubmed-meshheading:17889125-Survivors,
pubmed-meshheading:17889125-Tacrolimus,
pubmed-meshheading:17889125-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
|
|
pubmed:affiliation |
Departamento de Cirugía Cardiovascular, Clinica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain.
|
|
pubmed:publicationType |
Journal Article
|
